What is FDA’s GLP-1 API Green List (Import Alert 66-80)?

What is the FDA green list for GLP-1 APIs?

It is the list of firms and drugs on FDA’s Import Alert 66-80, “Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances” (published Oct 9, 2026). The alert says “Divisions may detain without physical examination (DWPE) shipments of GLP-1 APIs offered for entry, except for the products and firms identified on the Green List of this Alert.” FDA says the Green List “lists GLP-1 APIs of registered foreign manufacturers whose facilities and associated products, based on FDA’s evaluation of recent evidence, appear to be in compliance with CGMP requirements.” As read Nov 15, 2026, it has 21 entries in 8 countries (China (12), India (3), Belgium (1), Canada (1), Denmark (1), Ireland (1), Italy (1) and Portugal (1)), and FDA redacts every firm name.

FDA’s name for the list, from the alert: “List of firms and their drugs that have met the criteria for exclusion from recommendation for Detention Without Physical Examination (DWPE) under this Import Alert (a.k.a. Green List)” The alert uses the list only to exclude the listed firms and drugs from detention without physical examination under this alert; it does not describe the list as an approval of any drug.

The alert’s reason, verbatim

From the “Reason for Alert” section of Import Alert 66-80, as FDA published it on Oct 9, 2026:

Note: The major revision of this Import Alert (IA) is in response to CDER ICB's request supporting CDER Office of Compliance, Office of Manufacturing Quality (OMQ), Division of Drug Quality I’s memo of March 19, 2026 recommending revision of Import Alert (IA)#66-80.

This revision updates the guidance section including examples of information a manufacturer should submit to FDA to be considered for addition to the Green List, the list of firm and drugs that have met the criteria for exclusion from recommendation for DWPE under this Import Alert (a.k.a. Green List) and addition of new FDA Product Codes.

• Add Orforglipron API to three manufacturers on the Green List. • Add Orforglipron SDD, a drug product intermediate, to one manufacturer on the Green List. • Add the new FDA Product Code for Orforglipron, 61P[][]77 (Anti-Diabetic).2 • Add the FDA Product Code for Hormone N.E.C o 64R[]S99 (Hormone N.E.C., Active Pharm Ingred/Chems for Further Manuf) o 64R[]T99 (Hormone N.E.C., Active Pharm Ingred/Chems for Rx Compounding) o 64R[]R99 (Hormone N.E.C., NonSterile Powder) o 64R[]Z99 (Hormone N.E.C., Sterile Powder)

Changes to the import alert are bracketed by asterisks (***).

FDA has approved several Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) drug products for treatment of patients with type 2 diabetes mellitus and chronic weight management for obese and certain overweight patients, along with other indications. FDA is aware that some patients and health care professionals may seek unapproved GLP-1 drug products, such as those containing the active ingredients semaglutide and tirzepatide.

Shortages of approved GLP-1 drug products led to increased compounding of such products using active pharmaceutical ingredients (APIs) from foreign sources. During the shortages, APIs used to compound GLP-1 drug products were supplied by various API manufacturers located around the world, including China, India, and Europe. GLP-1 APIs are drugs as defined by section 201(g)(1)(D) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because they are intended for use as a component of a drug product and, thus, are subject to current good manufacturing practice (CGMP) requirements pursuant to section 501(a)(2)(B) of the FD&C Act.

Under section 501(a)(2)(B), a drug is deemed to be adulterated when the methods used in, or the facilities, or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformance with CGMP. Moreover, drugs are deemed to be adulterated under section 501(j) if they are manufactured by a firm that delays, denies, or limits an inspection of a facility in which a drug is manufactured, processed, packed, or held, or that fails to provide requested records in advance of or in lieu of an inspection pursuant to section 704(a)(4) of the FD&C Act. Similarly, records provided pursuant to a request under section 704(a)(4) may provide evidence of adulteration under section 501(a)(2)(B).

The Agency has identified specific areas of concern for drugs compounded from GLP-1 APIs that appear to be adulterated. Although API manufacturers are subject to CGMP requirements pursuant to section 501(a)(2)(B) of the FD&C Act, compounders whose drugs meet the conditions of section 503A of the FD&C Act are exempt from CGMP requirements, including the requirement to ensure API used in manufacturing meets specifications for impurities or potency, among other things. Therefore, there is a heightened risk that any quality concerns associated with the bulk drug substance would not be adequately controlled for or monitored during the compounding of finished dosage forms.

Given its concern that GLP-1 APIs used in compounding may be adulterated, FDA has conducted both onsite inspections and remote regulatory assessments of 48 GLP-1 API sites via requests for records or other information under section 704(a)(4) of the FD&C Act to evaluate registered GLP-1 API manufacturers in the U.S. supply chain. Of the 48 GLP-1 API sites FDA evaluated, it found that 21% were noncompliant under section 501 of the FD&C Act, either because their responses to FDA records requests provided evidence of noncompliance with CGMP requirements or because firms did not respond to an FDA records request under section 704(a)(4) in a timely manner. In addition, FDA has encountered a pattern of sites that register as GLP-1 API manufacturers, offer GLP-1 APIs for import, refuse to answer FDA’s requests for records, and then deregister, all within a short period of time.

Based on the information available to FDA described above, foreign-sourced GLP-1 APIs should be considered for detention without physical examination (DWPE) based on the appearance of adulteration. Adulteration puts the safety of the American public at risk.

The alert’s guidance, opening paragraph

Divisions may detain without physical examination (DWPE) shipments of GLP-1 APIs offered for entry, except for the products and firms identified on the Green List of this Alert. The Green List, as of the date of initial issuance of this import alert, lists GLP-1 APIs of registered foreign manufacturers whose facilities and associated products, based on FDA’s evaluation of recent evidence, appear to be in compliance with CGMP requirements.

The rest of the guidance lists what a manufacturer may send FDA to be considered for the Green List, such as certificates of analysis, stability data and batch records. It is on the alert page.

Green List entries

CHINA12
INDIA3
BELGIUM1
CANADA1
DENMARK1
IRELAND1
ITALY1
PORTUGAL1

Drugs listed, by number of entries

Liraglutide (Anti-Diabetic)10
Semaglutide (Anti-Diabetic)10
Tirzepatide (Anti-Diabetic)9
Anti-Diabetic N.E.C. (Anti-Diabetic)3
Orforglipron (Anti-Diabetic)3
Peptide N.E.C. (Antibiotics)3
Exenatide (Anti-Diabetic)2
Dulaglutide (Endocrine-Metabolic Agent)1
Hormone N.E.C. (Hormone)1
Orforglipron SDD (Anti-Diabetic)1

Every entry, in FDA’s order

Product codes and drugs listed
1Redacted by FDABELGIUM61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]75 Exenatide (Anti-Diabetic)
2Redacted by FDACANADA61P[][]74 Tirzepatide (Anti-Diabetic)
3Redacted by FDACHINA56F[][]99 Peptide N.E.C. (Antibiotics), and the importer description contains the word, [redacted]
61P[][]77 Orforglipron (Anti-Diabetic)

61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) and the importer description contains the word, [redacted]

61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) [redacted]
4Redacted by FDACHINA56F[][]99 Peptide N.E.C. (Antibiotics)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic)
5Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
6Redacted by FDACHINA61P[][]74 Tirzepatide (Anti-Diabetic)
7Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
8Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
9Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
10Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
11Redacted by FDACHINA61P[][]74 Tirzepatide (Anti-Diabetic)
61P[][]77 Orforglipron (Anti-Diabetic)
12Redacted by FDACHINA61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]74 Tirzepatide (Anti-Diabetic)
13Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
14Redacted by FDACHINA56F[][]99 Peptide N.E.C. (Antibiotics) [redacted]
61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) [redacted]

64R[][]99 Hormone N.E.C. (Hormone) [redacted]
15Redacted by FDADENMARK61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)
16Redacted by FDAINDIA61P[][]76 Liraglutide (Anti-Diabetic)
17Redacted by FDAINDIA61P[][]75 Exenatide (Anti-Diabetic)
18Redacted by FDAINDIA61P[][]76 Liraglutide (Anti-Diabetic)
19Redacted by FDAIRELAND58H[][]06 Dulaglutide (Endocrine-Metabolic Agent)
61P[][]77 Orforglipron (Anti-Diabetic)
20Redacted by FDAPORTUGAL61P[][]72 Semaglutide (Anti-Diabetic)
61P[][]77 Orforglipron SDD (Anti-Diabetic)
21Redacted by FDAITALY61P[][]76 Liraglutide (Anti-Diabetic)

Product codes the alert covers

Shipments under these FDA product codes are covered by the alert. The letter before the last two characters is FDA’s process indicator code, which the alert spells out (for example “Active Pharm Ingred/Chems for Rx Compounding”).

CodeFDA description
56F-S99Peptide N.E.C., Active Pharm Ingred/Chems for Further Manuf
56F-T99Peptide N.E.C., Active Pharm Ingred/Chems for Rx Compounding
56F-R99Peptide N.E.C., NonSterile Powder
56F-Z99Peptide N.E.C., Sterile Powder
58H-S06Dulaglutide, Active Pharm Ingred/Chems for Further Manuf
58H-T06Dulaglutide, Active Pharm Ingred/Chems for Rx Compounding
58H-R06Dulaglutide, NonSterile Powder
58H-Z06Dulaglutide, Sterile Powder
58H-S07Insulin Degludec, Active Pharm Ingred/Chems for Further Manuf
58H-T07Insulin Degludec, Active Pharm Ingred/Chems for Rx Compounding
58H-R07Insulin Degludec, NonSterile Powder
58H-Z07Insulin Degludec, Sterile Powder
58H-S08Lixisenatide, Active Pharm Ingred/Chems for Further Manuf
58H-T08Lixisenatide, Active Pharm Ingred/Chems for Rx Compounding
58H-R08Lixisenatide, NonSterile Powder
58H-Z08Lixisenatide, Sterile Powder
58H-S09Insulin Glargine, Active Pharm Ingred/Chems for Further Manuf
58H-T09Insulin Glargine, Active Pharm Ingred/Chems for Rx Compounding
58H-R09Insulin Glargine, NonSterile Powder
58H-Z09Insulin Glargine, Sterile Powder
61P-S72Semaglutide (Anti-Diabetic), Active Pharm Ingred/Chems for Further Manuf
61P-T72Semaglutide (Anti-Diabetic), Active Pharm Ingred/Chems for Rx Compounding
61P-R72Semaglutide (Anti-Diabetic), NonSterile Powder
61P-Z72Semaglutide (Anti-Diabetic), Sterile Powder
61P-S74Tirzepatide (Anti-Diabetic), Active Pharm Ingred/Chems for Further Manuf
61P-T74Tirzepatide (Anti-Diabetic), Active Pharm Ingred/Chems for Rx Compounding
61P-R74Tirzepatide (Anti-Diabetic), NonSterile Powder
61P-Z74Tirzepatide (Anti-Diabetic), Sterile Powder
61P-S75Exenatide (Anti-Diabetic), Active Pharm Ingred/Chems for Further Manuf
61P-T75Exenatide (Anti-Diabetic), Active Pharm Ingred/Chems for Rx Compounding
61P-R75Exenatide (Anti-Diabetic), NonSterile Powder
61P-Z75Exenatide (Anti-Diabetic), Sterile Powder
61P-S76Liraglutide (Anti-Diabetic), Active Pharm Ingred/Chems for Further Manuf
61P-T76Liraglutide (Anti-Diabetic), Active Pharm Ingred/Chems for Rx Compounding
61P-R76Liraglutide (Anti-Diabetic), NonSterile Powder
61P-Z76Liraglutide (Anti-Diabetic), Sterile Powder
61P--77Orforglipron (Anti-Diabetic)
64R-R99Hormone N.E.C., NonSterile Powder
64R-S99Hormone N.E.C., Active Pharm Ingred/Chems for Further Manuf
64R-T99Hormone N.E.C., Active Pharm Ingred/Chems for Rx Compounding
64R-Z99Hormone N.E.C., Sterile Powder
61P-R99Anti-Diabetic N.E.C., NonSterile Powder
61P-S99Anti-Diabetic N.E.C., Active Pharm Ingred/Chems for Further Manuf
61P-T99Anti-Diabetic N.E.C., Active Pharm Ingred/Chems for Rx Compounding
61P-Z99Anti-Diabetic N.E.C., Sterile Powder

The charge, verbatim

For drugs that appear to be adulterated due to Current Good Manufacturing Practice (CGMP) violations:

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practice within the meaning of Section 501(a)(2)(B). [Adulteration, Section 501(a)(2)(B)]

OASIS charge code: DRUG GMPS

Other import alerts that name GLP-1 drugs

These FDA drug import alerts were read on Nov 15, 2026 and their text searched for semaglutide, tirzepatide, liraglutide, retatrutide and GLP-1. Alerts not listed were not searched.

Times the page names semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1
66-80: Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug SubstancesOct 9, 2026GLP-1 32, semaglutide 15, tirzepatide 14, liraglutide 1417
66-41: Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.Nov 12, 2026GLP-1 51
66-40: Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPsNov 12, 2026None0
66-66: APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR 201.122Oct 22, 2024None0
66-72: Detention Without Physical Examination Of Misbranded Drugs And Marketed New Drugs Without Approved ApplicationsOct 15, 2026None0
66-78: Detention Without Physical Examination of Drugs, Based Upon Analytic Test ResultsJul 9, 2026None0
66-79: Detention Without Physical Examination of Drugs From Foreign Establishments Refusing FDA InspectionSep 23, 2026None0
66-57: Detention Without Physical Examination of Foreign Manufactured Unapproved Prescription Drugs Distributed to Individuals in the U.S.Mar 23, 2026None0
66-76: Detention Without Physical Examination of Drugs or Active Pharmaceutical Ingredients From Facilities That Have Not Submitted Self-Identifying Information or Paid Facility or Program Fees Required Under GDUFAMar 26, 2025None0
54-16: DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS THAT ARE MARKETED AS FOODS, INCLUDING PRODUCTS MARKETED AS DIETARY SUPPLEMENTS, THAT CONTAIN AN ACTIVE PHARMACEUTICAL INGREDIENTOct 15, 2026None0
55-05: Detention Without Physical Examination Of Finished Dosage Form Drug Products, Active Pharmaceutical Ingredients, and Inactive Ingredients for Potentially Hazardous Microbiological ContaminationMay 5, 2026None0
99-34: DETENTION WITHOUT PHYSICAL EXAMINATION OF DRUGS OR MEDICAL DEVICES FROM FIRMS WITHOUT A VALID DRUG OR MEDICAL DEVICE REGISTRATION AND/OR LISTINGNov 2, 2026None0
Alert and listFirmCountryProducts as FDA lists them
66-41, Red List
added Jun 23, 2026
Hebei Houde Hanfang Medical Devices Co., Ltd.
Jinhe Int'L Business Bldg. A Room 1603, Huaan West Street, Shijiazhuang, Hebei CHINA
CHINA66V--99 Miscellaneous Patent Medicines, Etc.: GLP-1 Transdermal Patches
66V--99 Miscellaneous Patent Medicines, Etc.: Adhesive Patch

66Y--99 Exhibits - Other Drug Related Items N.E.C.: GLP-1 Transdermal Patches

66Y--99 Exhibits - Other Drug Related Items N.E.C.: Adhesive Patch

79K--GX Tape And Bandage, Adhesive: GLP-1 Transdermal Patches

79K--GX Tape And Bandage, Adhesive: Adhesive Patch

80K--ME Bedding, Disposable, Medical: GLP-1 Transdermal Patches

80K--ME Bedding, Disposable, Medical: Adhesive Patch

80Q--IX System, transdermal Ddlivery, CDER or CBER led: GLP-1 Transdermal Patches

80Q--IX System, transdermal Ddlivery, CDER or CBER led: Adhesive Patch

Common questions

Is a firm on the Green List approved by FDA?

The alert calls the Green List the firms and drugs that “have met the criteria for exclusion from recommendation for Detention Without Physical Examination (DWPE) under this Import Alert.” It is a status under this import alert, not a drug approval.

Can I see which companies are on the Green List?

No. On the alert page read Nov 15, 2026, FDA prints a redaction in place of every firm name; only the country and product codes are shown.

How does a firm get on the Green List?

The alert says requests go to FDA’s Division of Import Operations with evidence such as records about all GLP-1 API manufacturing sites and information showing the APIs were made in compliance with CGMP requirements.

Which drugs does the alert cover?

The alert’s product description is “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances (or Active Pharmaceutical Ingredients [APIs]).” Its product codes name: Peptide N.E.C.; Dulaglutide; Insulin Degludec; Lixisenatide; Insulin Glargine; Semaglutide (Anti-Diabetic); Tirzepatide (Anti-Diabetic); Exenatide (Anti-Diabetic); Liraglutide (Anti-Diabetic); Orforglipron (Anti-Diabetic); Hormone N.E.C.; Anti-Diabetic N.E.C..

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.